Cognoa
Pediatric behavioral-health company whose flagship product, Canvas Dx, is an FDA-authorized autism diagnostic aid designed for faster use in primary care.
Palo Alto, CA
2013
11-50
Commercial Insurance, Medicaid, Employer Benefits
What They Do
Cognoa develops digital diagnostics and therapeutics for pediatric behavioral health, with autism as its first commercial wedge. Canvas Dx combines caregiver inputs, provider questionnaires, and specialist video review to help clinicians diagnose or rule out autism in children with developmental concerns, reducing dependence on oversubscribed specialist centers. Current materials explicitly emphasize reimbursement through insurers including Highmark and Wyoming Medicaid.
Competitive Position
Cognoa competes with EarliPoint Health on autism diagnostics and with behavioral health platforms like Brightline and Cartwheel Care on broader pediatric behavioral care. Canvas Dx is differentiated by its FDA authorization status and primary-care deployment model.
Funding Rounds
No funding rounds on record for this company.